| answer text |
<p>Licensed cannabis-based medicines are routinely available on the National Health
Service. However, clinical guidelines from the National Institute for Health and Care
Excellence demonstrate a clear need for more evidence to support routine prescribing
and funding decisions for unlicensed cannabis-based medicines.</p><p>Funding of unlicensed
products is subject to local NHS decisions on a case-by-case basis. These decisions
follow clearly developed procedures that ensure equitable distribution of funding,
prioritising those medicines that have proved their safety, quality and clinical and
cost effectiveness.</p><p>We continue to call on manufacturers to conduct research
to prove if their products are safe and effective and we are working with regulatory,
research and NHS partners to establish clinical trials to test the safety and efficacy
of these products.</p>
|
 |
